ATHE Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Alterity Therapeutics Ltd (ATHE) is not a strong buy at the moment for a beginner, long-term investor. While the company has received positive FDA feedback for its Phase 3 trial, which is a promising catalyst, the lack of significant trading trends, neutral technical indicators, and absence of proprietary trading signals suggest that this is not an optimal entry point. Additionally, the stock's recent price performance and lack of financial data make it difficult to assess its long-term growth potential.
The MACD is positively expanding above 0, indicating slight bullish momentum. RSI is neutral at 57.918, and moving averages are converging, showing no clear trend. The stock is trading near its pivot point of 3.401, with resistance at 3.644 and support at 3.159, suggesting limited immediate upside potential.
Positive FDA feedback confirming readiness for Phase 3 clinical trial in Multiple System Atrophy (MSA), which enhances investor confidence in the company's R&D capabilities.
No significant trading trends from hedge funds or insiders. The stock has a 50% chance of minor short-term gains but lacks strong momentum indicators.
No financial data available for analysis.
No analyst rating or price target changes available for ATHE.
